News | May 24, 2012

Positive Data Supports Use of Real-Time Ablation Temperature Sensing

Presentations show Tempasure system can prevent steam pops and assess lesion quality, promising improved ablation procedure

May 24, 2012 — Advanced Cardiac Therapeutics Inc., a developer of temperature-sensing cardiac ablation systems, today announced results of several studies related to the company’s Tempasure cardiac ablation catheter. The Tempasure system is designed to improve clinical outcomes with a novel microwave radiometry technology that allows the electrophysiologist to measure the temperature of cardiac tissue during the ablation procedure, providing real-time information that enables proper energy delivery and lesion control. Presentations took place at the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston.

Jacob Koruth, M.D., of Mt. Sinai School of Medicine in New York presented results of a preclinical study confirming the ability of the Tempasure system to predict ‘steam pops,’ a risk of irrigated radiofrequency (RF) catheter ablation that can cause cardiac perforation, which can have severe clinical consequences.

“This pre-clinical study demonstrates that the Tempasure’s ability to measure tissue temperature during irrigated RF ablation allows for accurate prediction of steam pops,” said Vivek Reddy, M.D., FACC, director of electrophysiology laboratories at Mt. Sinai Medical Center, who serves on the company’s medical advisory board. “This represents a major step forward in catheter ablation because, with the precise temperature measurements possible with Tempasure during the ablation procedure, we can now eradicate this major safety concern for the electrophysiologist. I anticipate that Tempasure will also give the physician more confidence in the quality of each RF application."

Atsushi Ikeda, M.D., Ph.D., working with Hiroshi Nakagawa, M.D., Ph.D., of the University of Oklahoma Health Sciences Center, presented additional preclinical data showing that the Tempasure system can improve control and safety of RF lesion formation. Results of the presentation show that Tempasure’s measurement of temperature is highly correlated to lesion depth and accurately predicts the formation of steam pops.

“The preclinical data presented at HRS confirms the ability of the Tempasure system to prevent the occurrence of steam pops as well as predict lesion quality – promising an ablation technique with improved safety and efficacy for patients with cardiac arrhythmias,” said Bill Olson, president and chief executive officer of Advanced Cardiac Therapeutics. “We look forward to bringing this innovative technology to patients and physicians in Europe later this year.”

The Tempasure cardiac ablation catheter received CE Mark clearance in 2011.

The Tempasure system is designed to improve patient outcomes of cardiac ablation procedures by providing electrophysiologists with real-time validation information and greater control in lesion creation. The system’s novel passive sensing microwave radiometry technology allows the electrophysiologist to measure the temperature of cardiac tissue during the ablation procedure, providing real-time information that enables proper energy delivery and lesion control. This technology enables, for the first time, measurement of tissue temperature with a saline-irrigated RF catheter.

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init